Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (RCUS) Revenue
Annual & quarterly revenue history · segment & region breakdown
RCUS · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsArcus Biosciences, Inc. trailing twelve-month (TTM) revenue is $0.24B, a decrease of 4.26% year-over-year from $0.25B in FY2025.
Revenue trend
2025 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.25B | -$0.01B | -4.26% |
| 2024-12-31 | $0.26B | +$0.14B | +120.51% |
| 2023-12-31 | $0.12B | +$0.01B | +4.46% |
| 2022-12-31 | $0.11B | -$0.27B | -70.76% |
| 2021-12-31 | $0.38B | +$0.30B | +391.03% |
| 2020-12-31 | $0.08B | +$0.06B | +420.00% |
| 2019-12-31 | $0.01B | +$0.01B | +79.58% |
| 2018-12-31 | $0.01B | +$0.01B | +491.15% |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare RCUS revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Arcus Biosciences, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Arcus Biosciences, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Arcus Biosciences, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
RCUS revenue · 4 questionsRCUS's trailing twelve-month (TTM) revenue is $0.24B. That is a decrease of 4.26% year-over-year from $0.25B in FY2025.
▸ Source: FMP · Arcus Biosciences, Inc. SEC filings · GAAP · Arcus Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026